Cargando…
MRTF-A can activate Nrf2 to increase the resistance to doxorubicin
Chemotherapeutic drugs resistance was considered to be the major obstacle for cancer therapy. MRTF-A, co-activators of serum response factor (SRF), promoted tumor cell invasion and metastasis in cancer. So far there has been no relevant reports about MRTF-A’ role in tumor chemotherapy. Here, we repo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352412/ https://www.ncbi.nlm.nih.gov/pubmed/28035058 http://dx.doi.org/10.18632/oncotarget.14246 |
_version_ | 1782514966173057024 |
---|---|
author | Xu, Yao Luo, Ying Wang, Zhen-yu Li, Xi Zheng, Peng Zhang, Tong-cun |
author_facet | Xu, Yao Luo, Ying Wang, Zhen-yu Li, Xi Zheng, Peng Zhang, Tong-cun |
author_sort | Xu, Yao |
collection | PubMed |
description | Chemotherapeutic drugs resistance was considered to be the major obstacle for cancer therapy. MRTF-A, co-activators of serum response factor (SRF), promoted tumor cell invasion and metastasis in cancer. So far there has been no relevant reports about MRTF-A’ role in tumor chemotherapy. Here, we reported that MRTF-A overexpression conferred resistance to doxorubicin mediated apoptosis by significantly increasing the expression of Nrf2 which was an important molecule associated with the resistance of anticancer drugs. If MRTF-A was knocked down, could the corresponding results be obtained? Moreover, we showed that overexpression MRTF-A had no remarkable effect to doxorubicin mediated apoptosis in cancer cells when knocking down Nrf2. Further studies showed that MRTF-A regulated the transcriptional activity of Nrf2 by forming a complex with SRF binding to the CarG box which existed on Nrf2 promoter region. On the whole, our study revealed a novel possible resistant pathway to doxorubicin. |
format | Online Article Text |
id | pubmed-5352412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53524122017-04-14 MRTF-A can activate Nrf2 to increase the resistance to doxorubicin Xu, Yao Luo, Ying Wang, Zhen-yu Li, Xi Zheng, Peng Zhang, Tong-cun Oncotarget Research Paper Chemotherapeutic drugs resistance was considered to be the major obstacle for cancer therapy. MRTF-A, co-activators of serum response factor (SRF), promoted tumor cell invasion and metastasis in cancer. So far there has been no relevant reports about MRTF-A’ role in tumor chemotherapy. Here, we reported that MRTF-A overexpression conferred resistance to doxorubicin mediated apoptosis by significantly increasing the expression of Nrf2 which was an important molecule associated with the resistance of anticancer drugs. If MRTF-A was knocked down, could the corresponding results be obtained? Moreover, we showed that overexpression MRTF-A had no remarkable effect to doxorubicin mediated apoptosis in cancer cells when knocking down Nrf2. Further studies showed that MRTF-A regulated the transcriptional activity of Nrf2 by forming a complex with SRF binding to the CarG box which existed on Nrf2 promoter region. On the whole, our study revealed a novel possible resistant pathway to doxorubicin. Impact Journals LLC 2016-12-27 /pmc/articles/PMC5352412/ /pubmed/28035058 http://dx.doi.org/10.18632/oncotarget.14246 Text en Copyright: © 2017 Xu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Xu, Yao Luo, Ying Wang, Zhen-yu Li, Xi Zheng, Peng Zhang, Tong-cun MRTF-A can activate Nrf2 to increase the resistance to doxorubicin |
title | MRTF-A can activate Nrf2 to increase the resistance to doxorubicin |
title_full | MRTF-A can activate Nrf2 to increase the resistance to doxorubicin |
title_fullStr | MRTF-A can activate Nrf2 to increase the resistance to doxorubicin |
title_full_unstemmed | MRTF-A can activate Nrf2 to increase the resistance to doxorubicin |
title_short | MRTF-A can activate Nrf2 to increase the resistance to doxorubicin |
title_sort | mrtf-a can activate nrf2 to increase the resistance to doxorubicin |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352412/ https://www.ncbi.nlm.nih.gov/pubmed/28035058 http://dx.doi.org/10.18632/oncotarget.14246 |
work_keys_str_mv | AT xuyao mrtfacanactivatenrf2toincreasetheresistancetodoxorubicin AT luoying mrtfacanactivatenrf2toincreasetheresistancetodoxorubicin AT wangzhenyu mrtfacanactivatenrf2toincreasetheresistancetodoxorubicin AT lixi mrtfacanactivatenrf2toincreasetheresistancetodoxorubicin AT zhengpeng mrtfacanactivatenrf2toincreasetheresistancetodoxorubicin AT zhangtongcun mrtfacanactivatenrf2toincreasetheresistancetodoxorubicin |